What we’re doing.

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics BioNTech and Genevant will develop five products for rare diseases with high unmet medical need under the 50/50 co-development and co-commercialization collaboration Collaboration … Continued


Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos, former CEO of ARIAD Pharmaceuticals … Continued